Episode Details

Eli Lillys $4.5 billion investment in domestic manufacturing, driven by soaring demand for weight loss medications, has boosted their stock price by 2.5%. The companys new drug, Foundayo, shows promise for older adults, and their existing drugs global sales are surging. Eli Lillys first quarter revenue hit $19.8 billion, a 56% increase, fueled by Mounjaro and Zepbound. The FDAs proposed rule against copycat medications protects their market share. Despite recent stock fluctuations, a $1,000 investment five years ago would be worth over $5,000 today, highlighting their sustained growth.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/c4ece3650243a2dd